One blood draw.
A look at fifty cancers.
The Galleri multi-cancer early detection test, by GRAIL — collected by Alicia at your home, office, hotel, or yacht. A single tube. A single visit. Discreetly.
More than seventy percent of cancer deaths in the United States today come from cancers without a recommended population screening test. Galleri was designed to look for those.
A short profile of the test.
Performance figures from GRAIL's published validation data — the Circulating Cell-Free Genome Atlas (CCGA) study and the PATHFINDER real-world deployment.
Many of which have no recommended routine screening test today.
In published data, fewer than one in two hundred results showed a cancer signal in people without cancer.
When a signal is detected, Galleri's top-two prediction of the tissue of origin was correct in roughly nine of ten cases.
A single set of tubes, drawn once a year. About fifteen minutes at your door.
Sensitivity (how often a cancer is detected when present) rises with stage — roughly 17% at Stage I, 40% at Stage II, 77% at Stage III, and 90% at Stage IV in the CCGA validation. Galleri is not a substitute for stage-specific screening like mammography or colonoscopy.
A look at the small things in your blood.
Healthy and cancerous cells both shed small fragments of DNA — called cell-free DNA — into the bloodstream as they renew. The patterns on those fragments differ.
Galleri reads a chemical signature called methylation across millions of sites on the cell-free DNA in a single blood sample. A machine-learning model trained on tens of thousands of cancer and non-cancer samples decides whether a "cancer signal" is present and, if so, predicts the most likely tissue of origin.
The result is a single report — either no cancer signal detected, or a cancer signal detected with a predicted location to direct any follow-up.
In a Galleri sample
- TubesTwo
- Volume~20 ml
- MethodMethylation signature on cfDNA
- Result typesCancer signal detected / not detected
- IncludesCancer Signal Origin prediction
- Turnaround~10 business days
- CadenceAnnually
- RegulatoryCLIA-certified LDT; not FDA-approved
A wide net.
Galleri is designed to detect a cancer signal across the following cancer types. Many — including pancreatic, ovarian, esophageal, and liver — have no recommended population screening today, which is much of why the test exists.
Digestive
- Bile duct (cholangiocarcinoma)
- Colorectal
- Esophageal
- Gallbladder
- Gastric (stomach)
- Liver
- Pancreatic
- Small intestine
Reproductive — female
- Breast
- Cervical
- Ovarian
- Uterine
- Vulvar
Reproductive — male
- Prostate
- Testicular
- Penile
Genitourinary
- Bladder
- Kidney
- Urothelial tract
Head & neck
- Head and neck
- Nasopharyngeal
- Oral cavity
- Oropharyngeal
- Thyroid
- Tongue
- Tonsil
Blood & lymphatic
- Leukemia
- Lymphoma (Hodgkin)
- Lymphoma (non-Hodgkin)
- Multiple myeloma
- Plasma cell neoplasm
Skin & soft tissue
- Melanoma
- Sarcoma
- Soft tissue sarcoma
Thoracic
- Lung
- Mesothelioma
Other
- Anal
- Bone
- Neuroendocrine tumors
The full list is updated periodically by GRAIL as validation data accumulates. The categories above are a navigational aid — Galleri does not test for them as separate panels.
Adults at elevated risk.
Galleri is recommended for adults age 50 and older, the age band where cancer risk meaningfully rises and where GRAIL's validation data is strongest.
Adults under 50 with significant family history or elevated risk should consult their own physician about whether Galleri is appropriate before pursuing it. Validation data is strongest in the 50+ band.
Galleri complements standard age-appropriate screenings. It does not replace mammography, colonoscopy, low-dose CT, or other recommended tests.
Four quiet steps.
Through your physician.
Galleri requires a physician's order from your own clinician. Bring a written or electronic order to your visit. We collect the sample only.
At your door.
A single blood draw at your home, office, hotel, or yacht. About fifteen minutes. Calmly handled.
Chain of custody.
Your sample is transported securely to GRAIL's CLIA-certified laboratory in Menlo Park, California.
In about two weeks.
Delivered to you and your ordering physician. We do not interpret results — that's the physician's role.
Two possibilities. One next step.
No cancer signal detected
The most common outcome.
No methylation pattern consistent with cancer was found in the sample.
This does not mean no cancer is present — false negatives exist, particularly for early-stage disease. Continue all age-appropriate standard screenings. The test is repeated annually.
Cancer signal detected
A signal to investigate.
A methylation pattern consistent with cancer was found, with a predicted Cancer Signal Origin.
A detected signal is not a diagnosis. Your physician will direct a diagnostic workup — typically imaging or biopsy targeted to the predicted origin — to confirm whether cancer is present.
$1,350
Per test · one-time
A premium multi-cancer screening test, not currently covered by most insurance plans. HSA and FSA funds are sometimes eligible — check with your administrator.
OneStickUSA members receive preferred pricing — ask Alicia.
Galleri is processed by GRAIL at its CLIA-certified laboratory in Menlo Park, California.
Schedule a Galleri visit.
Alicia returns calls within the hour during business hours. Health details and physician-order specifics are covered on the call — never on this form.
954.670.3184